Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party

Autor:	Michele Baccarani, Marilina Amabile, Ilaria Iacobucci, Roberto Latagliata, Giuliana Alimena, Giuseppe Saglio, Fausto Castagnetti, Fabrizio Pane, Simona Soverini, Franco Iuliano, Gianantonio Rosti, Simona Bassi, Nicoletta Testoni, Giovanna Rege-Cambrin, Giovanni Martinelli, Francesca Palandri, Daniela Cilloni, Angela Poerio
Rok vydání:	2006
Předmět:	Pediatrics medicine.medical_specialty business.industry Immunology Phases of clinical research Myeloid leukemia Imatinib Cell Biology Hematology Biochemistry Older patients Age groups Overall survival Medicine Progression-free survival business Adverse effect medicine.drug
Zdroj:	Web of Science
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood.v108.11.4805.4805
Popis:	To assess the effect of age on response and compliance we performed a sub-analysis within a phase II trial of the GIMEMA CMLWorking Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, we identified: 226/284 (80%) younger patients (below 65 years) and 58/284 (20%) older patients (above 65 years) before starting imatinib. Responses (hematologic and cytogenetic) were lower in older age group but progression free survival and overall survival probabilities (median observation time 3 years) were the same. Moreover, among complete cytogenetic responders, no differences were found in the level of molecular response between the 2 age groups. As probably expected, older patients experienced more adverse events (AEs), both hematologic and non-hematologic: this worsen compliance, however, did not prevent a long term outcome similar to younger ones. CML
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc2feb55df02ae8b72b3a147d66cafb https://doi.org/10.1182/blood.v108.11.4805.4805 Zobrazit plný text záznamu